Emerging Therapeutic Options for the Management of COPD

Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide and is projected to be the third by 2020. COPD is characterized by chronic airflow limitation caused by airway inflammation and parenchymal destruction that is usually progressive. Inhaled bronchodilators con...

Descripción completa

Detalles Bibliográficos
Autores principales: Reid, Debra J., Pham, Nga T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629926/
https://www.ncbi.nlm.nih.gov/pubmed/23641160
http://dx.doi.org/10.4137/CCRPM.S8140
_version_ 1782266637751156736
author Reid, Debra J.
Pham, Nga T.
author_facet Reid, Debra J.
Pham, Nga T.
author_sort Reid, Debra J.
collection PubMed
description Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide and is projected to be the third by 2020. COPD is characterized by chronic airflow limitation caused by airway inflammation and parenchymal destruction that is usually progressive. Inhaled bronchodilators continue to be the mainstay of the current management of COPD. Safety and efficacy data of the recently approved medications including aclidinium, glycopyrronium, roflumilast, and indacaterol are reviewed here.
format Online
Article
Text
id pubmed-3629926
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-36299262013-05-02 Emerging Therapeutic Options for the Management of COPD Reid, Debra J. Pham, Nga T. Clin Med Insights Circ Respir Pulm Med Review Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide and is projected to be the third by 2020. COPD is characterized by chronic airflow limitation caused by airway inflammation and parenchymal destruction that is usually progressive. Inhaled bronchodilators continue to be the mainstay of the current management of COPD. Safety and efficacy data of the recently approved medications including aclidinium, glycopyrronium, roflumilast, and indacaterol are reviewed here. Libertas Academica 2013-04-09 /pmc/articles/PMC3629926/ /pubmed/23641160 http://dx.doi.org/10.4137/CCRPM.S8140 Text en © 2013 the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
spellingShingle Review
Reid, Debra J.
Pham, Nga T.
Emerging Therapeutic Options for the Management of COPD
title Emerging Therapeutic Options for the Management of COPD
title_full Emerging Therapeutic Options for the Management of COPD
title_fullStr Emerging Therapeutic Options for the Management of COPD
title_full_unstemmed Emerging Therapeutic Options for the Management of COPD
title_short Emerging Therapeutic Options for the Management of COPD
title_sort emerging therapeutic options for the management of copd
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629926/
https://www.ncbi.nlm.nih.gov/pubmed/23641160
http://dx.doi.org/10.4137/CCRPM.S8140
work_keys_str_mv AT reiddebraj emergingtherapeuticoptionsforthemanagementofcopd
AT phamngat emergingtherapeuticoptionsforthemanagementofcopd

Ejemplares similares